Moffitt Cancer Center has joined MD Anderson’s National Cancer Institute (NCI) Phase 0/I/II Cancer Prevention Clinical Chemoprevention Trials Consortia. Sponsored by the NCI’s Division of Cancer Prevention, the consortia conducts early clinical...
30-Jul-2015 10:00 AM EDT
The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ. Moffitt...
28-Jul-2015 10:30 AM EDT
Race and Institutional Factors Play an Important Role in Pharmacogenomic Trial Participation, Say Moffitt Cancer Center Researchers
Moffitt Cancer Center researchers have published a study in the Journal of the National Cancer Institute that analyzed the participation rate of patients in pharmacogenomic trials.
28-Jul-2015 10:00 AM EDT
Moffitt Cancer Center Researchers Develop First Genetic Test to Predict Tumor Sensitivity to Radiation Therapy
Moffitt Cancer Center researchers have contributed to these advances by developing the first test that analyzes the sensitivity of tumors to radiation therapy. They discovered that colon cancer metastases have varying sensitivity to radiation...
23-Jul-2015 9:30 AM EDT
Moffitt Cancer Center received a $3.6 million grant from the National Institutes of Health to study the use of electronic cigarettes, or e-cigarettes, over the next five years.
30-Jun-2015 9:00 AM EDT
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining cells adapt to...
19-Jun-2015 4:00 PM EDT
Latina Women Undergoing Chemotherapy for Breast Cancer Need More Culturally Relevant, Language-Specific Stress Management Tools
Moffitt Cancer Center researchers, along with collaborators at the University of South Florida, recently published a study about the attitudes and cultural perspectives of Latinas undergoing chemotherapy for breast cancer. The article also discusses...
19-Jun-2015 3:00 PM EDT
MEDI4736 Combined with Tremelimumab Results in Acceptable Toxicity, Clinical Activity in Non-Small Cell Lung Cancer Patients
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as...
28-May-2015 2:05 PM EDT